Cardiol’s broad IP portfolio and regulatory pathway focus, including FDA and European Medicines Agency orphan designations, ...

Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced todayPivotal Phase 3 trial of mavorixafor in ...

As the COVID-19 pandemic clearly demonstrated, health is an integral part of Europe’s security. That principle underpinned a ...

A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...

In the past decade, CPP has achieved significant success, including seven regulatory milestones, including the first ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

Aarti Industries, Aditya Birla Fashion Retail, Granules India, Hindustan Copper, Manappuram Finance are banned from F&O trading on 13 November 2024.

MIPLYFFA was further granted Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of NPC. MIPLYFFA is indicated for use in combination with miglustat for the ...

Investigational nipocalimab reduced serum immunoglobulin G (IgG), improved functional scores, and was well tolerated in ...

CuraTeQ Biologics' EMA GMP certification marks a key milestone in Aurobindo Pharma's expansion into biosimilars, with three ...

DARMSTADT, Germany I 12, 2024 I Merck, a leading science and technology company, today announced that the Phase III MANEUVER trial of pimicotinib, an ...